menu
    • menu

    Company profile for Nuvalent

    NEW Drugs in Dev: 5
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline wit...
    Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NuvalentUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Broadway 14th Floor, Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nuvalent.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Guardant, Nuvalent partner on cancer diagnostics
    Guardant, Nuvalent partner on cancer diagnostics

    30 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7257152

    FIRSTWORD PHARMA
    30 Apr 2026
    Share Share
    Nuvalent Presents Neladalkib Data in Advanced NSCLC at 2026 ASCO
    Nuvalent Presents Neladalkib Data in Advanced NSCLC at 2026 ASCO

    21 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-pivotal-data-from-alkove-1-trial-of-neladalkib-in-tki-pre-treated-advanced-alk-positive-nsclc-at-the-2026-american-society-of-clinical-oncology-annual-meeting-302748865.html

    PR NEWSWIRE
    21 Apr 2026
    Share Share
    Nuvalent To Unveil Zidesamtinib Data At AACR 2026 Meeting
    Nuvalent To Unveil Zidesamtinib Data At AACR 2026 Meeting

    18 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-to-present-new-preclinical-and-clinical-data-for-zidesamtinib-an-investigational-ros1-selective-inhibitor-at-aacr-annual-meeting-2026-302716553.html

    PR NEWSWIRE
    18 Mar 2026
    Share Share
    Nuvalent Advances Ontarget 2026 Plan, Highlights Key Milestones
    Nuvalent Advances Ontarget 2026 Plan, Highlights Key Milestones

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-announces-ontarget-2026-operating-plan-progress-and-outlines-key-anticipated-2026-milestones-302658102.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Nuvalent To Present At J.P. Morgan Healthcare Conference
    Nuvalent To Present At J.P. Morgan Healthcare Conference

    22 Dec 2025

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302647193.html

    PR NEWSWIRE BIO
    22 Dec 2025
    Share Share
    Nuvalent Appoints Ron Squarer To Board Of Directors
    Nuvalent Appoints Ron Squarer To Board Of Directors

    10 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvalent-appoints-ron-squarer-to-board-of-directors-302638394.html

    PR NEWSWIRE
    10 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search